{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-022435","form_type":"8-K","ticker":"NVAX","cik":"0001000694","company_name":"NOVAVAX INC","filed_at":"2025-03-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:02.621940+00:00","generated_at":"2026-05-24T23:08:44.660751+00:00","sec_items":["1.02"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Novavax terminates Canada COVID vaccine APA, to recognize $576M revenue in Q1 2025","bullets":["Canada terminated APA effective March 7, 2025, citing Novavax's failure to obtain regulatory approval for vaccine from Biologics Manufacturing Centre by Dec 31, 2024.","Novavax expects to recognize $576M previously in deferred revenue and other liabilities as product revenue in Q1 2025.","$28M in advance payments must be refunded to Canada within 30 days of the termination notice.","$20M escrow related to an MOU may be released to Novavax as the MOU is no longer feasible."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-022435","json":"https://secwatch.observer/filing/0001104659-25-022435.json","markdown":"https://secwatch.observer/filing/0001104659-25-022435.md","text":"https://secwatch.observer/filing/0001104659-25-022435.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1000694/000110465925022435/0001104659-25-022435-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1000694/000110465925022435/tm258808d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T23:08:44.660751+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}